RNA Avidity Biosciences, Inc. Stock Quote

RNA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.90	Insider Own	8.80%	Shs Outstand	48.25M	Perf Week	-4.64%
Market Cap	612.15M	Forward P/E	-	EPS next Y	-3.55	Insider Trans	-0.60%	Shs Float	46.14M	Perf Month	-32.52%
Income	-128.40M	PEG	-	EPS next Q	-0.75	Inst Own	91.80%	Short Float	8.90%	Perf Quarter	-19.21%
Sales	8.40M	P/S	72.87	EPS this Y	-39.10%	Inst Trans	-0.17%	Short Ratio	15.92	Perf Half Y	-50.42%
Book/sh	7.79	P/B	1.66	EPS next Y	-17.30%	ROA	-32.80%	Target Price	48.40	Perf Year	-36.58%
Cash/sh	8.40	P/C	1.54	EPS next 5Y	-	ROE	-36.30%	52W Range	11.02 - 29.59	Perf YTD	-45.52%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-31.00%	52W High	-56.00%	Beta	-
Dividend %	-	Quick Ratio	13.10	Sales past 5Y	-	Gross Margin	-	52W Low	18.15%	ATR	1.26
Employees	125	Current Ratio	13.10	Sales Q/Q	-33.30%	Oper. Margin	-	RSI (14)	38.55	Volatility	12.42% 8.66%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-11.70%	Profit Margin	-	Rel Volume	0.83	Prev Close	12.95
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 10 AMC	Payout	-	Avg Volume	257.94K	Price	13.02
Recom	1.80	SMA20	-12.87%	SMA50	-22.72%	SMA200	-35.08%	Volume	47,045	Change	0.54%

Sep-07-21

Initiated

Evercore ISI

Outperform

$50

Jun-17-21

Initiated

Needham

Buy

$50

Apr-26-21

Resumed

Credit Suisse

Outperform

$37

Jul-07-20

Initiated

Wells Fargo

Overweight

$60

Jul-07-20

Initiated

Wells Fargo

Overweight

Jul-07-20

Initiated

SVB Leerink

Outperform

Jul-07-20

Initiated

Credit Suisse

Outperform

$34

Jul-07-20

Initiated

Credit Suisse

Outperform

Jul-07-20

Initiated

Cowen

Outperform

May-10-22 06:15PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights PR Newswire
May-09-22 06:35PM	Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates Zacks -9.13%
08:47AM	We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth Simply Wall St.
May-03-22 06:40AM	Novavax (NVAX) Surges 19.3%: Is This an Indication of Further Gains? Zacks
Apr-05-22 09:00AM	Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer PR Newswire
Mar-29-22 09:00AM	Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting PR Newswire +7.10%
Mar-07-22 09:00AM	Avidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific Conference PR Newswire
Mar-01-22 05:55PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights PR Newswire
Feb-28-22 09:00AM	Avidity Biosciences Honors Rare Disease Day® PR Newswire
08:05AM	Reata Pharmaceuticals, Inc. (RETA) Reports Q4 Loss, Lags Revenue Estimates Zacks
Feb-23-22 09:00AM	Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer PR Newswire
Feb-11-22 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conferences PR Newswire
Feb-10-22 10:23AM	Avidity Biosciences (NASDAQ:RNA) investors are sitting on a loss of 25% if they invested a year ago Simply Wall St.
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... GuruFocus.com
Dec-09-21 09:00AM	Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event PR Newswire -7.15%
Nov-12-21 10:12AM	We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth Simply Wall St.
Nov-09-21 06:55PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights PR Newswire
Nov-04-21 09:00AM	Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC) PR Newswire +9.00%
Nov-02-21 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conferences PR Newswire
03:01PM	Earnings Preview: Avidity Biosciences, Inc. (RNA) Q3 Earnings Expected to Decline Zacks
Oct-18-21 09:00AM	FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 PR Newswire -5.20%
Aug-31-21 09:30AM	Avidity Biosciences to Participate in Upcoming Investor Conferences PR Newswire +9.13%
Aug-25-21 04:05PM	Avidity Biosciences Announces Changes to its Board of Directors PR Newswire
Aug-24-21 08:30AM	European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001 PR Newswire
Aug-16-21 08:30AM	Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use PR Newswire -6.92%
Aug-09-21 06:15PM	Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights PR Newswire
Aug-03-21 09:16PM	Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock PR Newswire -7.76%
Aug-02-21 04:01PM	Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock PR Newswire +6.84%
03:01PM	Will Avidity Biosciences, Inc. (RNA) Report Negative Q2 Earnings? What You Should Know Zacks
12:38PM	Avidity Biosciences Shares Gain As Its Oligonucleotide Candidate Enters Early-Stage Trial In Muscle Wasting Disorder Benzinga
08:00AM	Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1) PR Newswire
Jun-17-21 10:43AM	A Look At Avidity Biosciences' (NASDAQ:RNA) Share Price Returns Simply Wall St.
May-19-21 09:00AM	Avidity Biosciences Announces Updates on the Pipeline and Platform at Virtual Investor and Analyst Event PR Newswire
May-12-21 04:05PM	Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights PR Newswire
May-11-21 09:39AM	Lilly, MiNA Ink Broad RNA Deal Worth $1.25B Benzinga
May-03-21 08:54AM	Avidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021 PR Newswire
Apr-16-21 09:00AM	Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting PR Newswire
Mar-25-21 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conferences PR Newswire
Mar-15-21 04:05PM	Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights PR Newswire
07:40AM	We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth Simply Wall St.
Feb-17-21 04:05PM	Avidity Biosciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference PR Newswire
Jan-21-21 08:30AM	Avidity Biosciences Appoints W. Michael Flanagan, Ph.D. as Chief Technical Officer PR Newswire
Jan-11-21 08:30AM	Avidity Biosciences Announces Changes to its Board of Directors PR Newswire
Jan-08-21 08:30AM	Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia PR Newswire +11.18%
Dec-22-20 04:05PM	Avidity Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-21-20 04:05PM	Avidity Biosciences Announces Addition to the Nasdaq Biotechnology Index PR Newswire +7.45%
Dec-19-20 01:06PM	Is RNA A Good Stock To Buy According To Hedge Funds? Insider Monkey
Nov-10-20 04:05PM	Avidity Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights PR Newswire
Nov-05-20 04:05PM	Avidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020 PR Newswire
Sep-14-20 04:05PM	Avidity Biosciences to Present at Several Upcoming Virtual Scientific Meetings PR Newswire +7.32%
03:58PM	Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Sep-08-20 08:00AM	Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1 PR Newswire +5.75%
Sep-03-20 04:05PM	Avidity Biosciences to Present at the 2020 Wells Fargo Virtual Healthcare Conference PR Newswire
Aug-10-20 04:05PM	Avidity Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights PR Newswire
Jul-27-20 08:00AM	Avidity Biosciences Appoints Jae Kim, M.D. as Chief Medical Officer PR Newswire +5.56%
Jul-23-20 08:14PM	Wells Fargo: These 3 Strong Buy Stocks Are Must-Watch Names TipRanks
Jun-26-20 10:12PM	Avidity Biosciences, Enviva Partners See Activist Action Barrons.com
Jun-19-20 01:24PM	Insiders Roundup: Axis Capital, HD Supply GuruFocus.com +11.45%
Jun-16-20 04:01PM	Avidity Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jun-12-20 11:56AM	Avidity Biosciences jumps 50% in first day of trading MarketWatch
06:33AM	Avidity Biosciences prices IPO at $18 a share to raise $259.2 million to fund R&D MarketWatch
Jun-11-20 08:54PM	Avidity Biosciences Announces Pricing of Initial Public Offering PR Newswire
02:42PM	Coronavirus update: U.S. case tally passes 2 million mark and 21 states are still seeing increases in infections MarketWatch
06:28AM	Avidity Biosciences upsizes planned IPO and raises price range MarketWatch
Jun-10-20 07:24AM	IPO market gears up for another busy week with 8 deals expected to raise $2 billion MarketWatch
Jun-08-20 06:55AM	Avidity Biosciences to offer 10 million shares in its planned IPO, priced at $14 to $16 each MarketWatch

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEVIN ARTHUR A	Chief Scientific Officer	Nov 18	Option Exercise	1.22	25,000	30,571	26,330	Nov 22 08:22 PM
LEVIN ARTHUR A	Chief Scientific Officer	Nov 18	Sale	27.89	25,000	697,218	1,330	Nov 22 08:22 PM
RTW INVESTMENTS, LP	10% Owner	Aug 04	Buy	18.00	800,000	14,400,000	4,795,000	Aug 06 11:20 AM
LEVIN ARTHUR A	Chief Scientific Officer	Jun 25	Option Exercise	1.13	20,100	22,735	21,430	Jun 28 07:21 PM
LEVIN ARTHUR A	Chief Scientific Officer	Jun 25	Sale	28.12	20,100	565,299	1,330	Jun 28 07:21 PM
LEVIN ARTHUR A	Chief Scientific Officer	Jun 24	Option Exercise	1.24	100	124	1,430	Jun 28 07:21 PM
LEVIN ARTHUR A	Chief Scientific Officer	Jun 24	Sale	27.75	100	2,776	1,330	Jun 28 07:21 PM
LEVIN ARTHUR A	Chief Scientific Officer	Jun 17	Option Exercise	1.24	200	248	1,530	Jun 22 08:24 PM
LEVIN ARTHUR A	Chief Scientific Officer	Jun 17	Sale	27.75	200	5,550	1,330	Jun 22 08:24 PM
LEVIN ARTHUR A	Chief Scientific Officer	Jun 15	Sale	26.02	23,019	599,067	0	Jun 16 08:21 PM
LEVIN ARTHUR A	Chief Scientific Officer	Jun 14	Sale	25.92	14,003	362,921	23,019	Jun 16 08:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience